Slides
Page 1
Investor Presentation 30th October 2026
Page 2
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Navin Fluorine International Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.
Page 3
H1 FY27 – Performance highlights Consolidated Financials Business Highlights SALES Rs. 2,235.8 Cr + 51% YoY Operating EBITDA Margin + 367 bps YoY Operating PBT + 93% YoY Operating EBITDA + 69% YoY HPP REVENUE & Y-O-Y GROWTH Specialty CDMO 41% 53% 80% Rs. 764.5 Cr 34.2 % Rs. 619.2 Cr Rs. 1144 Cr Rs. 673 Cr Rs. 419 Cr
Page 4
Q2 FY27 – Performance highlights Consolidated Financials Business Highlights SALES Rs. 1,190.7 Cr + 57% YoY + 14% QoQ Operating EBITDA Margin + 176 bps YoY + 5 bps QoQ Operating PBT + 87% YoY + 19% QoQ Operating EBITDA + 66% YoY + 14% QoQ HPP REVENUE & Y-O-Y GROWTH Specialty CDMO 49% 58% 78% Rs. 407.5 Cr 34.2% Rs. 336.0 Cr Rs. 604 Cr Rs. 348 Cr Rs. 239 Cr
Page 5
Revenues Operating EBITDA Operating PBT Q3 FY25 Q4 FY36 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 606 701 725 758 892 938 1,045 1,191 PAT Q2 FY27 – Sustainable growth Rs. Crs Rs. Crs Rs. CrsRs. Crs Q3 FY25 Q4 FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 147 179 207 246 308 321 357 407 Q4 FY36 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 84 148 243 185 117 213 269 95 Q3 FY25Q3 FY25 Q4 FY36 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 98 115 141 179 243 251 283 336
Page 6
Business Vertical - HPP Key Highlights Consolidated Financials Revenue In Rs. Crs 404 604 Q2FY26 Q2FY27 +49% GEOGRAPHIC MIX 44% 56% ✓ Revenue growth led by higher volume and improved realisations ✓ Pricing environment for HFC continues to be firm with QoQ increase in realisation ✓ Increasing visibility for the upcoming capacities of HFC ✓ HFO supply contract with Solstice Advanced Materials US, Inc. extended by 4 years over the original 7 years and has an additional revenue potential of ~$180 million, taking the total contract value to ~ $590 million over the total contract period of 11 years ✓ Capex for additional HFC capacity equivalent upto 15,000 MTPA of R32 is on track to be commissioned shortly
Page 7
Business Vertical - Specialty Chemicals Key Highlights Consolidated Financials Revenue In Rs. Crs 220 348 Q2FY26 Q2FY27 +58% GEOGRAPHIC MIX 33% 67% ✓ Sustained growth underpinned by strong order visibility in H2 & beyond ✓ Product pipeline continues to scale up across existing and new molecules ✓ De-bottlenecking MPP capacity at Dahej commissioned in September 26 ✓ Chemours project is targeted for completion by end of Q3 FY27; purchase orders are in place for delivery during Q4 FY27
Page 8
Business Vertical - CDMO Key Highlights Consolidated Financials Revenue In Rs. Crs 134 239 Q2FY26 Q2FY27 +78% GEOGRAPHIC MIX 03% 97% ✓ Strong momentum with FY27, backed by positive developments on pipeline molecules ✓ Continued deeper engagement with European CDMO major. Supported by: • Increasing demand for existing molecule • Expanding our footprint in the supply chain, qualification PO received ✓ Phase II - cGMP4 capex of Rs. 125 Crs is on track to operationalize by end Q4 FY27 ✓ Strategy -in-action : • Balanced portfolio with good mix of late/commercial and early-stage molecules • Increasing footprint across range of promising therapeutic areas with global innovators- Oncology, Cardiovascular, Neurology and Animal health
Page 9
Incubating advanced materials Putting our strategy into action for developing a new high growth, high margin business vertical for the future. Building on core fluorination capabilities, the vertical will focus on niche applications in high growth sunrise sector – Data Centers, Electronics, Defence & Semiconductors. ADOPTION CAPACITIES CHEMOURS PROJECT DRDO Capex : Rs. 90 Crs Capex : Rs. 120 Crs Setting up adoption capacities to commercialise product pipeline. Setting up Initial commercial capacity to enable adoption of innovative liquid cooling product Driving AtmaNirbhar Bharat through DRDO TDF project for indigenous process development for a critical defence material
Page 10
Ongoing capex program Additional HFC capacity equivalent upto 15,000 MTPA of R32 Constructive global demand-supply environment driven by transition to low GWP gasses and increasing RAC and blends demand in India and export market • Capex of Rs. 236.5 Crs to be funded by internal accruals. • Project expected to be commissioned shortly ~ Rs. 600-825 Crs per annum Initial commercial capacity for manufacturing to enable adoption of innovative liquid cooling product For expanding footprint in the emerging and innovative Advanced Materials products Capex of Rs. 120 Crs, with 35 % funded by customer; balance through internal accruals Targeted commissioning by Q3 FY27 Under Confidentiality Investment in SPV for setting up of hybrid power plant • Reinforces sustainability through increased renewable energy adoption and continued progress toward decarbonization goals • This project will lead to over 60% of energy needs met from renewable sources Investment of Rs. 15.73 Crs for 14.9 MW of Hybrid capacity across NFIL & NFASL HFC Chemours Project Renewable power project Capex Details Capex Rational Amount & Completion Peak Revenue Potential Advanced Materials Phase II – cGMP4 • Incubate new value accretive business vertical as a future growth driver • Augment capability and cater to commercial scale qualification supplies • Capex of Rs. 90 Crs • Completion by Q2 FY28 To set up adoption capacities for Advanced Materials Access future growth opportunity • Capex cost of phase II - Rs.125 Crs • Completion by end Q4 FY27 • Increasing demand for existing molecule of European CDMO major. • Expanding our footprint in their supply chain Phase II - cGMP4 capex of Rs. 125 Crs An asset turnover of ~3x
Page 11
Consolidated Profitability Statement Particulars (Rs. Crs.) Q2 FY27 Q2 FY26 Y-o-Y Change Q1 FY27 Q-o-Q Change H1 FY27 H1 FY26 Y-o-Y Change Net Revenue from Operations 1,190.74 758.42 57.00% 1,045.08 13.94% 2,235.82 1,483.82 50.68% Raw Material 513.43 312.90 449.75 963.18 620.61 Gross Profit 677.31 445.52 52.03% 595.33 13.77% 1,272.64 863.21 47.43% GP Margin 56.88% 58.74% -186 Bps 56.97% -8 Bps 56.92% 58.17% -125 Bps Employee Expenses 94.46 73.04 86.57 181.03 150.61 Other Expenses 175.40 126.31 151.69 327.09 259.64 Operating EBITDA 407.45 246.17 65.52% 357.07 14.11% 764.52 452.96 68.78% Operating EBITDA Margin 34.22% 32.46% 176 Bps 34.17% 5 Bps 34.19% 30.53% 367 Bps Interest Expenses 28.72 30.30 32.12 60.84 60.65 Depreciation 42.77 36.58 41.68 84.45 71.82 Operating PBT 335.96 179.29 87.38% 283.27 18.60% 619.23 320.49 93.21% Operating PBT Margin 28.21% 23.64% 457 Bps 27.11% 111 Bps 27.70% 21.60% 610 Bps Other Income 15.60 18.21 35.09 50.69 32.12 Profit before tax 351.56 197.50 78.01% 318.36 10.43% 669.92 352.61 89.99% Tax 82.32 49.13 75.05 157.37 87.07 Profit After Tax 269.24 148.37 81.47% 243.31 10.66% 512.55 265.54 93.02% Profit After Tax Margin 22.61% 19.56% 305 Bps 23.28% -67 Bps 22.92% 17.90% 503 Bps (Loss) from Associates and joint ventures (net) (0.01) - - (0.01) (0.01) Profit for the period 269.23 148.37 81.46% 243.31 10.65% 512.54 265.53 93.03% Other Comprehensive Income (a) Items that will not be reclassified to profit and loss 0.46 (1.26) 0.36 0.82 (2.53) (b) Items that may be reclassified to profit and loss 0.62 0.65 (0.13) 0.49 2.36 Total Comprehensive income for the Period 270.31 147.76 82.94% 243.54 10.99% 513.85 265.36 93.64%
Page 12
Consolidated Balance Sheet Statement Particulars (Rs. Crs) Sep'26 Mar'26 ASSETS Non-Current Assets Property, plant and equipment 3,192.41 3,112.84 Right use of assets 60.19 65.34 Capital Work in Progress 317.29 143.28 Investment Properties 47.68 48.25 Goodwill 87.76 87.76 Intangible assets 8.81 9.47 Financial assets Investments accounted for using the equity method 0.70 0.71 Investments 4.86 4.62 Loans 0.30 0.16 Other financial assets 71.93 79.30 Non current tax assets (net) 27.52 21.42 Other non- current assets 8.24 20.59 Total Non- Current Assets 3,827.69 3,593.74 Current Assets (i) Inventories 431.28 445.56 Financial Assets (i) Investments 1,272.43 1,223.70 (ii) Trade receivables 889.19 751.79 (iii) Cash and Cash Equivalents 48.50 22.55 (iv) Bank Balance other than (iii) above 88.60 74.32 (v) Loans 0.19 0.15 (vi) Other financial assets 60.31 45.65 Other current assets 212.40 221.66 Total current assets 3,002.90 2,785.38 TOTAL ASSETS 6,830.59 6,379.12 Particulars (Rs. Crs) Sep'26 Mar'26 EQUITY (a) Equity share capital 10.26 10.25 (b) Other Equity (i) Reserves & Surplus 4,289.20 3,801.94 (ii) Other reserves 162.88 162.39 Total Equity 4,462.34 3,974.58 LIABILITIES Non ‐ current Liabilities Financial liabilities (i) Borrowings 901.99 940.01 (ii) Lease liabilities 28.13 32.36 Provisions 14.63 11.06 Deferred tax liabilities (net) 167.77 136.88 Other non- current liabilities 91.09 73.07 Contract liabilities 138.79 143.11 Total Non ‐ Current Liabilities 1,342.40 1,336.49 Current Liabilities Financial liabilities (i) Borrowings 305.12 286.34 (a) total outstanding dues of micro enterprises and small enterprises 40.10 58.77 (b) total outstanding dues of creditors other than micro enterprises and small enterprises 484.92 470.50 (iii) Lease liabilities 12.62 13.04 (iv) Other financial liabilities 87.66 94.37 Contract liabilities 32.42 68.42 Provisions 5.39 5.43 Current tax liabilities (net) 2.38 0.39 Other current liabilities 55.24 70.79 Total Current Liabilities 1,025.85 1,068.05 Total Equity and Liabilities 6,830.59 6,379.12
Page 13
Consolidated Cash Flow Statement Particulars (Rs. Crs.) H1 FY27 H1 FY26 Cash Flow from Operating Activities Profit before Tax 669.92 352.61 Adjustment for Non-Operating Items 101.13 102.75 Operating Profit before Working Capital Changes 771.05 455.36 Changes in Working Capital (183.74) (108.69) Cash Generated from Operations 587.31 346.67 Less: Direct Taxes paid (130.85) (65.79) Net Cash from Operating Activities 456.46 280.88 Cash Flow from Investing Activities (321.68) (594.32) Cash Flow from Financing Activities (108.83) 342.94 Net increase/ (decrease) in Cash & Cash equivalent 25.95 29.50 Add: Cash and cash equivalents as at 1st April 22.55 19.68 Cash and cash equivalents as at 30th September 48.50 49.18
Page 14
Standalone Profitability Statement Particulars (Rs. Crs.) Q2 FY27 Q2 FY26 Y-o-Y Change Q1 FY27 Q-o-Q Change H1 FY27 H1 FY26 Y-o-Y Change Net Revenue from Operations 737.26 562.37 31.10% 694.68 6.13% 1,431.94 1,105.32 29.55% Raw Material 323.81 251.08 292.40 616.21 490.52 Gross Profit 413.45 311.29 32.82% 402.28 2.78% 815.73 614.80 32.68% GP Margin 56.08% 55.35% 73 Bps 57.91% -183 Bps 56.97% 55.62% 134 Bps Employee Expenses 66.08 52.61 62.43 128.51 107.22 Other Expenses 109.53 93.74 94.87 204.40 188.44 Operating EBITDA 237.84 164.94 44.20% 244.98 -2.91% 482.82 319.14 51.29% Operating EBITDA Margin 32.26% 29.33% 293 Bps 35.27% -301 Bps 33.72% 28.87% 484 Bps Interest Expenses 2.10 2.08 4.88 6.98 2.92 Depreciation 21.68 19.76 21.10 42.78 38.56 Operating PBT 214.06 143.10 49.59% 219.00 -2.26% 433.06 277.66 55.97% Operating PBT Margin 29.03% 25.45% 359 Bps 31.53% -249 Bps 30.24% 25.12% 512 Bps Other Income 52.57 33.45 35.84 88.41 48.32 Profit before tax 266.63 176.55 51.02% 254.84 4.63% 521.47 325.98 59.97% Tax 62.06 42.54 64.20 126.26 79.21 Profit After Tax 204.57 134.01 52.65% 190.64 7.31% 395.21 246.77 60.15% Profit After Tax Margin 27.75% 23.83% 392 Bps 27.44% 30 Bps 27.60% 22.33% 527 Bps Profit for the period 204.57 134.01 52.65% 190.64 7.31% 395.21 246.77 60.15% Other Comprehensive Income Items that will not be reclassified to Profit & Loss (net of tax) 0.43 -1.27 0.27 0.70 -2.35 Total Comprehensive income for the Period 205.00 132.74 54.44% 190.91 7.38% 395.91 244.42 61.98%
Page 15
Standalone Balance Sheet Statement Particulars (Rs. Crs) Sep'26 Mar'26 ASSETS Non-Current Assets Property, plant and equipment 812.45 819.17 Right of use assets 38.23 42.61 Capital work in progress 302.79 64.44 Investment properties 36.84 37.27 Intangible assets 6.71 7.08 Financial assets Investment in Subsidiary & Joint Venture 1,143.69 1,143.69 Investments 4.86 4.62 Loans 0.11 0.16 Other financial assets 21.39 22.70 Non current tax assets (net) 25.65 19.76 Other non-current assets 7.79 15.88 Total Non- Current Assets 2,400.51 2,177.38 Current Assets (i) Inventories 195.89 199.41 Financial Assets (i) Investments 1,269.03 1,210.40 (ii) Trade receivables 648.93 600.32 (iii) Cash and cash equivalents 29.93 10.52 (iv) Bank Balance other than (iii) above 66.34 54.35 (v) Loans 76.11 50.37 (vi) Other financial assets 29.98 36.95 Other current assets 109.86 50.17 Total Current Assets 2,426.07 2,212.49 TOTAL ASSETS 4,826.58 4,389.87 Particulars (Rs. Crs) Sep'26 Mar'26 EQUITY (a) Equity share capital 10.26 10.25 (b) Other equity (i) Reserves & surplus 3,874.29 3,504.48 (ii) Other reserves 151.05 151.05 Total Equity 4,035.60 3,665.78 LIABILITIES Non ‐ Current Liabilities Financial liabilities-Lease liabilities 28.08 32.30 Contract liabilities 46.90 48.13 Provisions 7.75 5.52 Deferred tax liabilities (net) 68.38 61.57 Other non- current liabilities 32.50 13.42 Total Non ‐ Current Liabilities 183.61 160.94 Current Liabilities Financial liabilities (I) Borrowings - 0.10 (ii) Trade payables (a) total outstanding dues of micro enterprises and small enterprises 17.31 43.75 (b) total outstanding dues of creditors other than micro enterprises and small enterprises 470.24 406.22 (iii) Lease liabilities 11.58 11.47 (iv) Other financial liabilities 58.01 40.92 Contract liabilities 9.39 13.38 Provisions 4.84 5.14 Current tax liabilities (net) 1.97 0.39 Other current liabilities 34.03 41.78 Total Current Liabilities 607.37 563.15 TOTAL EQUITY AND LIABILITIES 4,826.58 4,389.87
Page 16
Standalone Cash Flow Statement Particulars (Rs. Crs.) H1 FY27 H1 FY26 Cash Flow from Operating Activities Profit before Tax 521.47 325.98 Adjustment for Non-Operating Items (32.98 ) 0.41 Operating Profit before Working Capital Changes 488.49 326.39 Changes in Working Capital (63.14) (75.34) Cash Generated from Operations 425.35 251.05 Less: Direct Taxes paid (123.98) (65.06) Net Cash from Operating Activities 301.37 185.99 Cash Flow from Investing Activities (242.80) (839.81) Cash Flow from Financing Activities (39.16) 681.64 Net increase/ (decrease) in Cash & Cash equivalents 19.41 27.82 Add: Cash and cash equivalents as at April 01 10.52 3.06 Cash and cash equivalents as at 30th September 29.93 30.88
Page 17
Company Overview
Page 18
Innovation has been at the heart of Navin Fluorine's nearly six-decade journey. From pioneering fluorochemistry capabilities to developing advanced materials, pharmaceutical solutions, specialty chemicals and next-generation technologies, every innovation redefines how we create meaningful value for customers, industries and society INNOVATING withPURPOSE Because innovation creates its greatest impact when it is guided by purpose.
Page 19
Building value through scale, innovation & partnerships Products Platform Partnerships 3 Geographies 4 Countries 3 Business Verticals 4 Manufacturing Units 3 R & D Centres OUR BUSINESSES PRESENCE ACROSS Speciality Chemicals High Performance Products (HPP) Contract Development and Manufacturing Organisation (CDMO) 3P STRATEGY
Page 20
6 Decades of expertise in fluorine chemistries One of the first companies to establish a refrigerant business in India Only Indian manufacturer of hydrofluoroolefins (HFO) Amongst India’s largest producers of inorganic chemicals - • anhydrous hydrofluoric acid (AHF) • and diluted hydrofluoric acid (HF) Demonstrated excellence across businesses One of the largest BF3 manufacturers globally World-class CDMO cGMP compliant facilities catering to global pharma innovators Amongst the most trusted global players in specialty fluorochemicals One of the largest Integrated Specialty Fluorochemical companies in India Proven capabilities for fluorination chemistries with precision-driven expertise from research to commercial scale
Page 21
Our winning edge Reputed Brand Mafron Rich LegacyIntegrated Fluorine Provider Diversified Portfolio Prominent Clientele Strategic Partnerships Committed to ESG World-class Infrastructure Credible Certifications Strong Global Presence Thriving Workforce Building Trusted Solutions for Life
Page 22
Rooted in 3P strategy Partnerships Platform Products 3P Focus Capacity Expansion Building Scalable Platforms Nurturing Long- Team Partnerships Diversified portfolio that includes fluorine based intermediates, specialty chemicals and inorganic chemicals Prioritising owning of specific technologies and chemistries that serve as building blocks (BB) for various business applications Utilising capabilities to diversify product pipeline and reinforce technology leadership Strategic multiyear partnerships to strengthen global supply chain presence alongside industry innovators and leaders Leveraging partner expertise and resources to extend reach and impact
Page 23
Focus on contract development and technology transfer of predominantly preclinical and clinical candidates in partnership with global pharmaceutical and biotech partners Navin Research & Innovation Centre, Surat, Gujarat Strengthening innovation and R&D capabilities Total R&D spend in FY 2025-26 Rs 48.71 Crs Key R&D Differentiators RESEARCH FOCUSSED Focussed on research-driven innovation to develop complex KSMs for global pharma and biotech innovators BACKWARD INTEGRATION Integrating high-end fluorine reagents enables cost-effective KSM developments and strengthens relationships with global pharma and biotech innovators. DEEP INDUSTRY EXPERTISE Nearly 6 decades of fluorine chemistry experience supported by the latest technology platforms, delivering multi-step complex, value added products for our partners. COLLABORATIVE EXCELLENCE Synergistic tie-ups with customers and technology teams ensure timely and efficient delivery of commitments in a time sensitive industry. STRATEGIC R&D INVESTMENT Strong management focus on emerging trends through ongoing R&D investments to deliver a robust, innovative product pipeline DIGITAL TRANSFORMATION Advancing digitalisation through the planned implementation of Electronic Lab Notebooks (ELN) and LIMS to improve efficiency, traceability and compliance. 3 Modern R&D Centres Navin Molecular R&D Centre, Dewas, MP and Runcorn, Manchester Exhibited commercial-scale capabilities across both fluorination and non fluorinated chemistries Houses 65 chemists and 40 engineers in the Technology and Design Undertakes ongoing R&D investments in core infrastructure and cutting-edge analytical equipment Develops and expands fluorinated specialty chemicals beyond traditional verticals Comprise 70 team members (For Dewas R&D) and 18 team members (For Runcorn MOL R&D) Have successfully executed phase driven projects from pre-clinical to Phase III and commercial molecule to customers
Page 24
At Navin Fluorine, sustainability defines how we operate and grow. Our structured Environment, Social and Governance (ESG) framework is guided by the principles of Responsible Care (RC) and Pharmaceutical Supply Chain Initiative (PSCI). With accountability, transparency and long-term stakeholder value creation at its core, it ensures that every decision made and innovation pursued creates a positive impact on our planet, people and communities. Committed to Sustainable Value Creation
Page 25
Progress towards our sustainability goals Environmental 100% compliance with EPR requirements for Plastic Packaging Materials by 2025 30% reduction in carbon emissions by 2030 from the base year 2023 50% use of renewable electricity by 2030 Engagement with 100% key value chain partners by 2030 Social 10% diversity in the Company employees by 2030 25% gender diversity in leadership teams by 2030 25% gender diversity across the Board by 2030 Governmance 100% resolution of complaints ZERO cases of corruption and bribery UN SDGs Impacted UN SDGs Impacted Environmental 100% compliance achieved with respect to EPR requirements for Plastic Packaging Materials Increase of 11.1% in specific carbon emissions in tCO₂/tonne of production 12.15% usage of renewable electricity in 2026 Engaged with 30% of value chain partners in 2026 Social 3.94% workplace diversity in 2026 0% gender diversity in leadership teams in 2026 10% gender diversity in the Board of Directors Governmance 89.24% % resolution of complaints in 2026 ZERO cases of corruption and bribery in 2026 ESG Goals Progress on ESG Targets in FY 2025-26 UN SDGs Impacted
Page 26
17 Board Committee Highly engaged Board actively involved in NFIL’s strategic transformation 8 Board Meetings during FY 2026 Board Demographics 7 Directors inducted since FY22 58 years median Directors’ age Board Independence 8 of 10 Directors are Non-Executive 1 Woman Director (Independent) on the Board 6 of 10 Directors are Independent 60% 80% Highly Experienced Board to chair Committees Audit Committee Nomination & Remuneration Committee Stakeholders’ Relationship Committee CSR Committee Risk Management Committee 60% Fund Raising Committee* ESG Steering Committee 335+ Years of Consolidated experience of the Board The Chairman and Managing Director have historically been separate positions * Fund Raising Committee dissolved w.e.f. February 09, 2026 Governance framework
Page 27
Diversity of thought and experience 27 Ms. Apurva S. Purohit (Independent Director) She is a prominent Indian Business leader with over 33 years of experience in the media and entertainment industry. She has managed a diverse portfolio of businesses in partnership with private equity players and promoters, from early stage businesses to mature ones. She has a postgraduate diploma in management from IIM, Bangalore. Mr. Vishad P. Mafatlal (Chairman) He is an accomplished industrialist with varied experience of 29+ years in the field of textiles and chemicals. He has a Bachelor of Science degree in Economics from the University of Pennsylvania’s Wharton School. Mr. Atul K. Srivastava (Independent Director) He has an experience of over 49 years in large corporates, in the areas of Finance, Accounting, Taxation and Commerce. He is a Science Graduate and a Fellow Chartered Accountant - B. Sc (Hons), FCA. Mr. Ashok U. Sinha (Independent Director) He has a wealth of experience, competencies and expertise from his leadership journey at Bharat Petroleum Corporation Ltd. He has a BTech in Electrical Engineering from IIT, Kanpur, and a Post Graduate Diploma in Management from IIM, Bangalore, with specialisation in Finance. Mr. Sunil S. Lalbhai (Non-Executive Non-Independent Director) He is an industrialist having varied experience of over 36 years in chemicals and general management. He is a science graduate and holds M.S degree in chemistry from USA and also M.S degree in economic planning & policy from the Boston University of USA. Mr. Sujal A. Shah (Independent Director) He has an experience of over 33 years in the fields of Valuation, Due Diligence, Corporate Restructuring, Audit and Advisory. He is a commerce graduate and member of the Institute of Chartered Accountants of India. Mr. Sudhir R. Deo (Non-Executive Non-Independent Director) Mr. Deo has 45 years of association with Arvind Mafatlal Group (AMG), retired as Managing Director of NOCIL in July 2023. He has headed multiple mandates of the business including Manufacturing, Technology, Research, Strategy, Marketing and Supply Chain. He is an expert in ESG and Sustainability, focusing on implementation to elevate business value. He holds an M. Tech. in Chemical Engineering from IIT Kanpur. Mr. Abhijit J. Joshi (Independent Director) Mr. Joshi is the Founding and Managing Partner of Veritas Legal being regarded among Asia’s Top 15 Private Wealth and M&A Lawyers with a legal career spanning 3 decades. Over the years, he has advised various business houses, promoter families, global conglomerates and large private equity houses across industry sectors on numerous complex deals and cases. He is a dual-qualified solicitor in India and England. Mr. Nitin G. Kulkarni (Managing Director) Mr. Kulkarni has over 3 decades of rich experience across the specialty chemicals value chain, specifically covering fluoro-chemicals and CDMO. He is a highly respected leader with a proven track record of: driving growth, establishing new business verticals, embedding manufacturing excellence, and execution of large projects, both brownfield and greenfield. He is also passionate about HSE and sustainability. He holds a Masters degree in Organic Chemistry from the University of Mumbai. Mr. Kartikeya A. Dube (Independent Director) Mr. Dube has more than 30 years of diverse and rich experience in business, finance, governance, risk, M&A, fund raising, procurement, government affairs, cross border investment/transaction strategy and structures, regulatory framework, life cycle transactions, exchange control and investment regulations, etc. He is a Chartered Accountant and a Bachelor of Commerce. He has attended various leadership programs including INSEAD.
Page 28
Governance framework: policies, practices & protocols ✓ Auditor qualification against the Company ✓ Re-statements of financial statements ✓ Allegations of financial imprudence ✓ Defaults for repayments, creditors and dividends Composition of the Statutory Committees as on March 31, 2026 Out of 4 Members of the Audit Committee, 3 are Independent and 1 Non-Executive Reported NO Out of 3 Members of Nomination and Remuneration Committee, 2 are Independent and 1 Non-Executive Out of 3 Members of Stakeholders’ Relationship Committee, 2 are Independent and 1 Executive Out of 6 Members of the Risk Management Committee, 1 is Independent, 2 are Executive, 1 is Non- Executive and 2 are Non-Board Members Structured policies and processes addressed investor grievances Accepted all the resolutions proposed by the Board to shareholders Employed a rigorous Board evaluation policy; Board comprised eminent members Implemented an active succession pipeline for critical roles and the Board Carried out an Internal audit through an independent audit firm reporting directly to the Audit Committee Implemented two ESOP plans Out of 3 Members of the Corporate Social Responsibility Committee, 1 is Independent, 1 Executive and 1 Non-Executive
Page 29
Creating lasting social impact through CSR Rs. 8.72 Crs total CSR spend in FY 2025-26 SHRI SADGURU SEVA SANGH TRUST OLYMPIC GOLD QUESTCSR FOCUS AREAS Health Sports Skill Development Other Social Causes Education Sustainable Livelihood Animal Care BLIND PEOPLE’S ASSOCIATION SHAKTI FOUNDATION CHARUTAR AROGYA MANDAL'S SHRI KRISHNA HOSPITAL SIR J. J. HOSPITAL “The intelligent way to be selfish is to work for the welfare of others” The Dalai Lama
Page 30
Track record of progressive dividends 65% FY10 85% 65% FY11 600% 65% 85% FY12 75% 75% FY13 85% 75% FY14 85% 75% FY15 110% 100% FY16 75% 130% 110% FY17 150% 180% 170% FY18 200% 190% FY19 150% 400% FY20 300% 250% FY21 300% 250% FY22 350% 250% FY23 150% 350% 250% FY24 350% 250% FY25 430% 325% FY26 FY27 140% 150% 750% 150% 160% 160% 210% 315% 500% 390 550% 550% 550% 600% 750% 600% 755% 75% 400% Special Final Interim 22% 24% 37% 40% 36% 38% 29% 28% 33% 31% 30% 23% 20% 19% 32% 25% * On standalone basis Dividend as % of Face Value Payout %* 16%
Page 31
For further information, please contact: Navin Fluorine International Ltd. CIN : L24110MH1998PLC115499 Mr. Anish Ganatra Chief Financial Officer anish.ganatra@nfil.in www.nfil.in Investor Relations Advisors: Ms. Payal Dave E : payal.dave@cygnuspartners.in Ms. Pooja Swami E : pooja.swami@cygnuspartners.in